In addition, AMG 925 by Amgen [127], a dual-kinase inhibitor aimed at CDK4 and fms-like tyrosine kinase (FLT) 3, may help overcome FLT3 resistance in AML [128]. This evidence concerns the gene FLT3 and acute myeloid leukemia.